[HTML][HTML] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
PA Jänne - Annals of Oncology, 2016 - Elsevier
Background The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
SS Ramalingam, K O'Byrne, M Boyer… - Annals of Oncology …, 2016 - europepmc.org
Background The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
[引用][C] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): Pooled subset analyses from two randomized trials
SS Ramalingam, K O'Byrne, M Boyer… - Annals of …, 2016 - produccioncientifica.ucm.es
Background: The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
SS Ramalingam, K O'Byrne, M Boyer, T Mok… - Annals of …, 2016 - hero.epa.gov
BACKGROUND: The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
SS Ramalingam, K O'Byrne, M Boyer… - Annals of oncology …, 2016 - pubmed.ncbi.nlm.nih.gov
Background The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
[HTML][HTML] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
SS Ramalingam, K O'Byrne, M Boyer… - Annals of …, 2016 - annalsofoncology.org
Background The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
[引用][C] Corrections to “Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two …
SS Ramalingam, K O'Byrne, M Boyer, T Mok… - Annals of …, 2016 - cir.nii.ac.jp
Corrections to “Dacomitinib versus erlotinib in patients with EGFR-mutated advanced
nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials” | CiNii …
nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials” | CiNii …
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
S Ramalingam, K O'Byrne, M Boyer, T Mok… - Annals of …, 2016 - eprints.qut.edu.au
Background: The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
[引用][C] Corrections to “Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two …
SS Ramalingam, K O'Byrne, M Boyer… - Annals of …, 2016 - annalsofoncology.org
The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated
efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are …
efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are …
[引用][C] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
SS Ramalingam, K O'Byrne, M Boyer… - Annals of Oncology …, 2016 - europepmc.org
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung
cancer (NSCLC): pooled subset analyses from two randomized trials. - Abstract - Europe …
cancer (NSCLC): pooled subset analyses from two randomized trials. - Abstract - Europe …